Ligustrazine

DB19074InvestigationalSmall molecule

Ligustrazine is under investigation in clinical trial NCT05942352 (Clinical Study of Ligustrazine in Treating Alcohol Addiction).

Mechanism: Pharmacologically active on Peroxisome proliferator-activated receptor gamma and Cyclic nucleotide phosphodiesterase
Curator reviewed
Formula / weight: C₈H₁₂N₂ · 136.198 g/mol (avg)
Also known as: 2,3,5,6-tetramethylpyrazine · Chuanxingzine · Chuanxiongqin · Ligustrazin · Pyrazine, 2,3,5,6-tetramethyl-
Code names: FEMA NO. 3237 · NSC-36080 · NSC-46451

Resolves to

Compound

Clinical / RWD

Structure

InChIKeyFINHMKGKINIASC-UHFFFAOYSA-NSMILESCC1=NC(C)=C(C)N=C1C

Targets

What you can answer from here — as of July 09, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ligustrazine, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.